IBRX at a glance
ImmunityBio, Inc. (IBRX, SEC CIK 1326110) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ImmunityBio, Inc. (IBRX) reported revenue of $113.3 million (up 668.3% from FY2024) and a net loss of $351.4 million. Diluted EPS was -$0.38.
- As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding ImmunityBio, Inc. (IBRX) shares worth $1.3 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Simon Barry J. on October 5, 2026 of 25,000 shares at $10.75 per share.
- In the last 90 days, IBRX insiders reported 0 open-market purchases ($0) and 2 open-market sales ($1.1M) on Form 4, a net sale of $1.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $113.3M
- +668.3% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$1.1M
- 13F holders
- 32 funds
- $1.3B · −3 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Development and commercialization of biologic drugs, with focus on regulatory approvals and post-marketing requirements
- New emphasis on commercialization efforts for approved product ANKTIVA and building sales, marketing, and distribution capabilities
- Strategic shift toward handling complex FDA accelerated approval pathways and orphan drug exclusivity following 2026 Orphan Drug Act codification
- Post-marketing commitments for ANKTIVA include QUILT-3.032 trial completion by end of 2029 and annual FDA reporting up to 4 years
- Increased focus on cybersecurity risks and use of AI in business, highlighting vulnerabilities and operational disruption potentials
Risk Factors
- Regulatory risk from potential NCCN guideline decision on BCG-unresponsive NMIBC papillary-only disease expansion expected Q1/Q2 2026
- Geopolitical exposure via dependency on 33 countries with ANKTIVA approval including US, UK, EU, Saudi Arabia, and MENA launches
- Supply vulnerability as company supports FDA Expanded Access Program for rBCG to address U.S. supply constraints
- Competitive risk from CPI combination therapies in metastatic NSCLC with conditional SFDA approval and planned commercial launch in 60 days
- Financial risk in rapid revenue growth: ANKTIVA sales $113M FY2025, 700% YoY increase, requiring scaling of 85-person EU sales force and global partnerships
Management Discussion & Analysis
- Revenue started from ANKTIVA sales since May 2024; no dollar amounts or YoY change disclosed
- Operating expenses expected to increase substantially due to commercialization and R&D expansion; no margin % figures provided
- No segment-specific performance data or best/worst performing segment disclosed
- Cash and equivalents plus sales and potential equity offerings expected to fund operations for next 12 months; no buyback/dividend/capex details provided
- Management highlights significant funding risks, need for additional capital to sustain operations, and regulatory/commercialization uncertainties impacting future outlook
AI summary of the IBRX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly expanded ANKTIVA indication: FDA approval on October 14, 2026 for BCG-unresponsive NMIBC with high-grade papillary-only tumors
- Regulatory compliance: QUILT-3.032 completion and annual FDA reporting required through 2029
- Near-term market risk: ongoing TICE BCG shortage constraining ANKTIVA uptake and clinical-trial execution
- Liquidity risk: $334.3 million cash and securities versus $480.0 million convertible note and over $426.3 million RIPA liability
- RIPA exposure: revenue-interest payments ranging from 5.625% to 12.50% of worldwide net sales excluding China
Management Discussion & Analysis
- Q3 revenue $48.8M, up from $32.1M YoY, driven by ANKTIVA product revenue of $48.7M, up 53%
- Operating loss $78.0M vs $55.6M YoY, operating margin (159.7%) vs (173.5%)
- ANKTIVA best-performing product, revenue increased $17.0M; no segment disclosures
- Cash, equivalents and marketable securities $334.3M vs $242.8M at December 31, 2025
- Outlook: R&D expenses expected to increase significantly; substantial additional funding required, with going-concern doubt absent support
AI summary of the IBRX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release announces ImmunityBio’s business update and financial results for Q3 and nine months ended September 30, 2026
- Financial position reported as of September 30, 2026, with detailed figures in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 net product revenue $48.7M, up 53% YoY, signaling accelerating ANKTIVA adoption and commercial traction
- Nine-month revenue $143.6M, up 92% YoY, already exceeding full-year 2025 revenue of $113.0M
Item 7.01: Regulation FD Disclosure
- ANKTIVA plus BCG met the primary endpoint in Cohort A of the randomized QUILT-2.005 trial
- Result applies to BCG-naïve, non-muscle invasive bladder cancer patients
Item EX-99.1: Item EX-99.1
- QUILT-2.005 met its primary efficacy endpoint in 370 BCG-naïve, high-grade NMIBC patients versus BCG alone
- Statistically significant efficacy improvement supports potential frontline expansion beyond ANKTIVA’s current BCG-unresponsive indication
Item EX-99.1: Item EX-99.1
- FDA expanded ANKTIVA plus BCG approval to all BCG-unresponsive NMIBC, including papillary-only tumors
- Papillary disease represents approximately 85% of the NMIBC patient population, materially broadening ANKTIVA’s addressable market
Item 7.01: Regulation FD Disclosure
- FDA expanded ANKTIVA plus BCG approval to BCG-unresponsive NMIBC with papillary-only tumors
- Broader eligible patient population, supporting potential commercial uptake of ANKTIVA
AI summaries of IBRX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for IBRX
Don't miss the next IBRX filing
- Alerts as it files. A push when IBRX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut IBRX, by share count.
- Ask anything. An AI agent that reads every IBRX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Simon Barry J. | Sell | Oct 5, 2026 | 25,000 | $10.75 |
| Cohen Cheryl | M | Oct 2, 2026 | 55,979 | $2.98 |
| Cohen Cheryl | Sell | Oct 2, 2026 | 81,056 | $10.50 |
| Cohen Cheryl | M | Oct 2, 2026 | 55,979 | - |
| Cohen Cheryl | Sell | Jul 2, 2026 | 131,210 | $9.50 |
| Cohen Cheryl | M | Jul 2, 2026 | 55,979 | - |
| Cohen Cheryl | M | Jul 2, 2026 | 55,979 | $2.98 |
| Selecky Christobel | M | Jul 1, 2026 | 35,064 | $2.98 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $14.7M | $113.3M |
| Operating Income | - | -$344.2M | -$256.0M |
| Net Income | -$583.2M | -$413.6M | -$351.4M |
| Op. Margin | - | -2334.2% | -226.0% |
| Net Margin | - | -2804.8% | -310.2% |
| Balance Sheet | |||
| Total Assets | $504.5M | $382.9M | $501.9M |
| Equity | - | -$489.1M | -$500.5M |
| ROE | - | 84.6% | 70.2% |
| Per Share | |||
| EPS | $-1.15 | $-0.62 | $-0.38 |
| Cash Flow | |||
| Operating CF | - | -$391.2M | -$304.9M |
| CapEx | $30.6M | $6.9M | $3.8M |
Source: XBRL data in ImmunityBio, Inc. (IBRX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate IBRX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 32 | $1.28B |
| Q2 2026 | 35 | $1.20B |
| Q1 2026 | 34 | $855.0M |
| Q4 2025 | 30 | $202.1M |
| Q3 2025 | 31 | $195.3M |
| Q2 2025 | 29 | $192.7M |
| Q1 2025 | 22 | $110.7M |
| Q4 2024 | 18 | $79.0M |
- Vanguard Capital Management LLC+3.11M (+20%)
- BlackRock+2.04M (+6%)
- Principal Financial Group+1.71M (+5779%)
- Vanguard Portfolio Management LLC+1.53M (+9%)
- Goldman Sachs Group+895.6K (+28%)
- Two Sigma Investments−5.27M (-47%)
- Millennium Management−1.76M (-32%)
- Morgan Stanley−1.30M (-38%)
- D.E. Shaw & Co−839.2K (-7%)
- Bank of America Corp−461.9K (-21%)
- Renaissance Technologies LLC−1.03M
- FMR LLC (Fidelity)−29.5K
- Equitable Holdings Inc−15.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 231 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
IBRX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 8-K | Oct 14, 2026 | - | Analysis | - |
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | May 18, 2026 | - | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 9, 2026 | - | Analysis | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
IBRX SEC filings: frequently asked questions
Are IBRX insiders buying or selling?
In the last 90 days, ImmunityBio, Inc. (IBRX) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $1.1 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold IBRX stock?
As of September 30, 2026, the largest ImmunityBio, Inc. (IBRX) holders among the 13F filers tracked by SignalX were BlackRock ($341.0 million), State Street Corp ($199.1 million), Vanguard Portfolio Management LLC ($183.0 million), Vanguard Capital Management LLC ($177.5 million), D.E. Shaw & Co ($101.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was IBRX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ImmunityBio, Inc. (IBRX) reported revenue of $113.3 million (up 668.3% from FY2024) and a net loss of $351.4 million. Diluted EPS was -$0.38. The figures come from the XBRL data in the 10-K.
What are the main risks in IBRX's latest 10-K?
In the 10-K filed February 23, 2026, ImmunityBio, Inc. (IBRX) flagged: Regulatory risk from potential NCCN guideline decision on BCG-unresponsive NMIBC papillary-only disease expansion expected Q1/Q2 2026. Geopolitical exposure via dependency on 33 countries with ANKTIVA approval including US, UK, EU, Saudi Arabia, and MENA launches. (AI summary of the Risk Factors section.)
What did IBRX report in its latest 8-K?
ImmunityBio, Inc. (IBRX) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces ImmunityBio’s business update and financial results for Q3 and nine months ended September 30, 2026.
What are the latest IBRX SEC filings?
ImmunityBio, Inc. (IBRX) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on October 6, 2026.
What is IBRX's SEC CIK number?
ImmunityBio, Inc. (IBRX)'s SEC Central Index Key (CIK) is 1326110. EDGAR lists every IBRX filing under that number.
Ask anything about IBRX
The research agent reads IBRX's filings, financials, insider trades and 13F holders, then answers with sources.